TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Stanford University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
Kousai Bio Co., Ltd.
M.D. Anderson Cancer Center
Comenius University
Eilean Therapeutics
University of Manitoba
Centre Hospitalier Universitaire de Nice
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pennsylvania
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
University of Miami
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
University of Turin, Italy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fred Hutchinson Cancer Center
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
Arovella Therapeutics Ltd
St. Justine's Hospital
University of Arizona
Northside Hospital, Inc.
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
AstraZeneca
First People's Hospital of Hangzhou
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sheba Medical Center
University Hospital, Angers
Institute of Hematology & Blood Diseases Hospital, China
Children's Oncology Group
Institute of Hematology & Blood Diseases Hospital, China
Shenzhen TargetRx Co., Ltd.
University of Alabama at Birmingham
University of Nebraska
Novartis
Tcelltech Inc.
The First Affiliated Hospital of Soochow University
Shanghai Jiao Tong University School of Medicine
PETHEMA Foundation